EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ5676 is a highly potent and selective inhibitor of the DOT1L histone methyltransferase, displaying an IC₅₀ of 0.8 nM and a Ki of 80 pM for DOT1L, with over 37,000-fold selectivity versus other methyltransferases (APExBIO). The compound is effective in downregulating H3K79 methylation and MLL-fusion target genes, resulting in cytotoxicity in acute leukemia cell lines with MLL translocations (Anichini et al., 2022). In vivo, EPZ5676 induces complete tumor regression in MV4-11 xenograft models at 35–70 mg/kg/day without toxicity. Its selectivity and robust activity make it a reference tool for epigenetic regulation in cancer research. Researchers should note its solubility profile (≥28.15 mg/mL in DMSO, insoluble in water) and recommended storage at –20°C (see product page for details).

Biological Rationale

DOT1L (disruptor of telomeric silencing 1-like) is the sole methyltransferase catalyzing methylation of histone H3 at lysine 79 (H3K79). This post-translational modification is essential for transcriptional regulation and is aberrantly activated in MLL (mixed lineage leukemia) rearranged leukemias (Anichini et al., 2022). MLL fusion proteins, generated by chromosomal translocations, drive oncogenic gene expression programs dependent on DOT1L-mediated H3K79 methylation. Inhibiting DOT1L thus specifically disrupts leukemogenic transcriptional circuits without broadly affecting global histone methylation, making it a rational target for selective antileukemic therapies. Epigenetic drugs targeting histone methylation, such as EPZ5676, have demonstrated reduced off-target immunomodulation compared to other classes, supporting their utility in precision oncology (Anichini et al., 2022).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 binds competitively to the S-adenosyl methionine (SAM) binding pocket of DOT1L. This binding induces conformational changes, creating an open hydrophobic pocket beyond the amino acid portion of SAM (APExBIO). The compound does not interact with most other methyltransferases, as evidenced by >37,000-fold selectivity against CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1. EPZ5676 efficiently blocks H3K79 methylation, suppressing MLL-fusion target gene expression and arresting proliferation in MLL-rearranged leukemia cells. Its unique mechanism enables potent antiproliferative activity with minimal effect on non-MLL-driven cells.

Evidence & Benchmarks

• EPZ5676 exhibits an IC₅₀ of 0.8 nM and a Ki of 80 pM for DOT1L in biochemical assays (APExBIO product data).
• Displays >37,000-fold selectivity over other methyltransferases including CARM1, PRMTs, and EZH2 (APExBIO).
• Reduces H3K79 methylation and MLL-fusion gene expression, resulting in IC₅₀ of 3.5 nM in MV4-11 leukemia cells after 4–7 days (APExBIO).
• In MV4-11 xenografted nude rats, 35–70 mg/kg/day IV administration for 21 days induced complete tumor regression with no significant toxicity or weight loss (APExBIO).
• Epigenetic inhibitors demonstrate distinct immune-related gene signatures, with DOT1L inhibitors like EPZ5676 showing limited non-specific immunomodulation compared to DNA methyltransferase or BET inhibitors (Anichini et al., 2022).

This article updates and extends the mechanistic and translational focus of "EPZ5676: Advanced Mechanistic Insights into DOT1L Inhibit..." by providing new benchmarks and highlighting selectivity data in the context of emerging immunomodulatory findings. It also clarifies the workflow integration aspects that are only briefly mentioned in "EPZ5676: DOT1L Inhibition as a Strategic Pivot in Immuno-..." by detailing solubility, stability, and assay design parameters.

Applications, Limits & Misconceptions

EPZ5676 is primarily used in the following research applications:

• Biochemical enzyme inhibition assays targeting DOT1L activity.
• Cell proliferation and cytotoxicity studies in acute leukemia models, especially those with MLL translocations.
• Translational in vivo studies evaluating tumor regression and toxicity in xenograft models.
• Epigenetic studies dissecting H3K79 methylation and downstream gene regulation.

While EPZ5676 is a gold-standard tool for DOT1L inhibition, its effects are highly context-dependent. It does not broadly modulate immune signatures like DNA methyltransferase inhibitors (e.g., guadecitabine) or BET inhibitors, as shown in the immune-related gene signature landscape (Anichini et al., 2022). For a deep dive into comparative mechanistic insights, see "EPZ5676: Deep Dive into DOT1L Inhibition and Epigenetic C...", which this article extends by integrating in vivo benchmarks and recent selectivity data.

Common Pitfalls or Misconceptions

• EPZ5676 is not effective in leukemia models lacking MLL rearrangements or DOT1L-driven gene expression.
• It does not induce broad immunomodulatory gene expression changes as seen with DNMT or HDAC inhibitors.
• The compound is insoluble in water; improper solvent selection can result in precipitation and experimental failure.
• EPZ5676's selectivity does not guarantee lack of off-target effects in non-enzyme-based readouts; validation is recommended.
• Long-term storage of solutions at room temperature or above –20°C leads to loss of potency.

Workflow Integration & Parameters

EPZ5676 (A4166) from APExBIO is supplied as a solid (MW 562.71). For optimal dissolution, use DMSO at ≥28.15 mg/mL or ethanol (ultrasonic assistance) at ≥50.3 mg/mL. The compound is insoluble in water; avoid aqueous buffers for stock preparation (DOT1L inhibitor EPZ-5676). Store powder and DMSO stocks at –20°C. Avoid long-term solution storage to preserve activity. In cell assays, apply at 3–10 nM for 4–7 days; for in vivo xenograft studies, standard dosing is 35–70 mg/kg/day by intravenous route for 21 days. Use validated DOT1L activity and H3K79 methylation readouts for endpoint assessment. Benchmarks for cytotoxicity, gene expression, and tumor regression are detailed above and should be referenced directly for experimental design.

Conclusion & Outlook

EPZ5676 is a best-in-class DOT1L inhibitor, offering nanomolar potency, unmatched selectivity, and proven efficacy in MLL-rearranged leukemia models. Its narrow, mechanism-based action profile minimizes off-target immunomodulation, distinguishing it from broader-spectrum epigenetic agents. APExBIO provides validated product documentation and workflow guidance (product page), supporting reproducible high-impact research. Ongoing studies aim to combine DOT1L inhibition with other targeted or immunotherapeutic strategies, leveraging the precision of epigenetic modulation in cancer therapy.